Trending...
- Inside the Fight for Affordable Housing: Avery Headley Joins Terran Lamp for a Candid Bronx Leadership Conversation
- UK Financial Ltd Announces A Special Board Meeting Today At 4PM: Orders MCAT Lock on CATEX, Adopts ERC-3643 Standard, & Cancels $0.20 MCOIN for $1
- T-TECH Partners with Japan USA Precision Tools for 2026 US Market Development of the New T-TECH 5-Axis QUICK MILL™
National analyses reveal widespread psychotropic prescribing to infants, toddlers, and young children. CCHR is urging immediate federal oversight, calling the trend a systemic failure, placing children at chemical risk.
LOS ANGELES - eTravelWire -- By CCHR International
Tens of thousands of American children who begin with a prescription for Attention Deficit Hyperactivity Disorder (ADHD) drugs ultimately end up on multiple powerful psychiatric drugs, sometimes even before they are old enough to attend elementary school. A new Wall Street Journal analysis of 2019–2023 Medicaid data found that children aged 3 to 14 who were started on an ADHD drug were more than five times as likely to be prescribed additional psychiatric drugs within four years compared to peers not on ADHD drugs. Most of the added drugs were antidepressants or antipsychotics—agents associated with severe, sometimes irreversible, side effects.[1] However, the mental health industry watchdog, Citizens Commission on Human Rights International (CCHR), conducted its own review of state-by-state Medicaid data through Freedom of Information Act (FOIA) requests, and the findings were even more alarming.
From the 32 states that provided records, nearly 3 million Medicaid-enrolled children ages 0–17 were prescribed psychiatric drugs in 2023, at a cost of $1.78 billion. Among them were 270,196 toddlers and preschool-aged children—an especially vulnerable population for whom many of these drugs are not FDA-approved. Because 18 states failed to provide data, the true national total is almost certainly far higher, likely surpassing 4 million children.
In the comprehensive breakdown of Medicaid child beneficiaries, more than 1.4 million were prescribed stimulants, 920,411 were given antidepressants, 605,746 received antianxiety drugs, 465,599 were put on antipsychotics, and 384,299 were prescribed mood stabilizers.
The Wall Street Journal reports that, according to 2021 federal data, 7.1 million American children aged 3 to 17 have been given an ADHD diagnosis. Roughly half are estimated to be on ADHD drugs. Data obtained by CCHR from IQVIA, a global healthcare analytics firm, revealed 3.15 million U.S. children (0–17) were prescribed ADHD stimulants in 2020, including 58,000 children under 5 years old.
More on eTravel Wire
The FDA approves these drugs only for children six and older, meaning young children are being prescribed potent stimulants "off-label" and without long-term safety research.
CCHR's Medicaid data collection three years later indicates the situation has not merely continued but likely worsened into a full-scale public-health failure demanding immediate federal intervention.
Jan Eastgate, president of CCHR International, says that these prescribing patterns reveal a federally funded "drug and polypharmacy pipeline"—one that urgently demands congressional and state oversight to protect children from what the watchdog calls "chemical assault and negligence disguised as care."
ADHD stimulant drugs carry a black box warning that they can cause addiction, even when taken exactly as prescribed.[2] A recent American Journal of Psychiatry study found that high doses of certain ADHD stimulants were associated with a more than five-fold increased risk of psychosis or mania.[3]
Danish physician and researcher Dr. Peter C. Gøtzsche warns that stimulants can also suppress normal childhood emotional and behavioral expression, causing apathy or indifference. In some studies, more than half of children developed depression or compulsive, and meaningless behaviors while taking them.[4]
Antidepressants also carry their own black box warning for suicidal thoughts and behavior in children and young adults.[5]
Antipsychotics are linked to metabolic damage, violent behavior, and neurological disorders.[6] One of their most severe effects is tardive dyskinesia (TD)—a disfiguring movement disorder caused by antipsychotics. Its symptoms resemble Parkinson's disease: involuntary movements of the lips, tongue, jaw, fingers, toes, or other body parts. TD can persist long after the drug is stopped—sometimes permanently. It is a reported risk in the pediatric population.[7]
Even worse, individuals developing TD are often prescribed more psychiatric drugs to counter the symptoms, exposing them to additional risks such as blurred vision, tremors, irregular heartbeat, drooling, restlessness, or akathisia—a well-documented driver of extreme agitation and suicidal or violent behavior.[8]
Eastgate says the expanding trend of drugging children with cocktails of psychotropics constitutes a national emergency: "This is a chemical assault on children, masking the real causes of their distress and too often worsening the very problems these drugs claim to treat. Federal and state intervention is urgently needed to abolish these negligent polypharmacy practices."
More on eTravel Wire
Clinical experts agree the system is out of control. Alexandra Perez, a clinical psychologist at Emory University School of Medicine, told The Wall Street Journal she has seen children as young as four years old who were already on multiple psychiatric drugs. Many of these children had histories of trauma or adversity that were mislabeled as ADHD and drugged instead of addressed through non-drug support.
A 2021 review in Frontiers in Psychiatry summarized more than 20 years of research documenting substantial growth in pediatric psychotropic polypharmacy. In the studies reviewed:
Four years after those findings, the Wall Street Journal shows the trend has only worsened, as confirmed also by CCHR's own Medicaid analysis. Between 2019 and 2022:
CCHR, founded 56 years ago by the Church of Scientology and professor of psychiatry Thomas Szasz, said the latest data reveal an entrenched national failure to protect children. "Pumping kids with ADHD stimulants—often amphetamines—combined with mind-altering antidepressants, antipsychotics, or sedative-hypnotics, is evidence of a mental health system that has normalized harm under the guise of treatment," Eastgate said. "This is not care—it is harm. The practice should be abolished."
Sources:
[1] Shalini Ramachandran, et al., "Millions of Kids Are on ADHD Pills. For Many, It's the Start of a Drug Cascade," Wall Street Journal, 20 Nov. 2025, www.wsj.com/health/wellness/kids-adhd-drugs-medication-06dfa0b7?st=oRRSe8&reflink=desktopwebshare_permalink
[2] www.cchrint.org/2023/05/16/fda-finally-adds-addiction-to-black-box-warning-on-adhd-drugs/; www.fda.gov/media/168066/download
[3] www.cchrint.org/2024/09/20/new-study-warns-of-high-dose-adhd-drugs-inducing-psychosis/; www.nbcnews.com/health/mental-health/high-doses-adhd-drugs-linked-greater-risk-psychosis-rcna170707
[4] Peter C. Gøtzsche, MD, "Critical Psychiatry Textbook, Chapter 9: ADHD (Part Two)," Mad In America, 14 Aug. 2023
[5] medshun.com/article/why-do-antipsychotics-cause-violence
[6] pmc.ncbi.nlm.nih.gov/articles/PMC3004713/; medshun.com/article/why-do-antipsychotics-cause-violence; psychiatryonline.org/doi/10.1176/appi.ps.201500272
[7] pubmed.ncbi.nlm.nih.gov/38862692/
[8] www.cchrint.org/2021/10/11/consumers-beware-of-antipsychotics-long-term-debilitating-effects/
[9] pmc.ncbi.nlm.nih.gov/articles/PMC8236612/
Tens of thousands of American children who begin with a prescription for Attention Deficit Hyperactivity Disorder (ADHD) drugs ultimately end up on multiple powerful psychiatric drugs, sometimes even before they are old enough to attend elementary school. A new Wall Street Journal analysis of 2019–2023 Medicaid data found that children aged 3 to 14 who were started on an ADHD drug were more than five times as likely to be prescribed additional psychiatric drugs within four years compared to peers not on ADHD drugs. Most of the added drugs were antidepressants or antipsychotics—agents associated with severe, sometimes irreversible, side effects.[1] However, the mental health industry watchdog, Citizens Commission on Human Rights International (CCHR), conducted its own review of state-by-state Medicaid data through Freedom of Information Act (FOIA) requests, and the findings were even more alarming.
From the 32 states that provided records, nearly 3 million Medicaid-enrolled children ages 0–17 were prescribed psychiatric drugs in 2023, at a cost of $1.78 billion. Among them were 270,196 toddlers and preschool-aged children—an especially vulnerable population for whom many of these drugs are not FDA-approved. Because 18 states failed to provide data, the true national total is almost certainly far higher, likely surpassing 4 million children.
In the comprehensive breakdown of Medicaid child beneficiaries, more than 1.4 million were prescribed stimulants, 920,411 were given antidepressants, 605,746 received antianxiety drugs, 465,599 were put on antipsychotics, and 384,299 were prescribed mood stabilizers.
The Wall Street Journal reports that, according to 2021 federal data, 7.1 million American children aged 3 to 17 have been given an ADHD diagnosis. Roughly half are estimated to be on ADHD drugs. Data obtained by CCHR from IQVIA, a global healthcare analytics firm, revealed 3.15 million U.S. children (0–17) were prescribed ADHD stimulants in 2020, including 58,000 children under 5 years old.
More on eTravel Wire
- ❄️ Winter Feature: Stay Comfortable at Cold-Weather Events
- Tiger-Rock Martial Arts Appoints Jami Bond as Vice President of Growth
- Super League (N A S D A Q: SLE) Enters Breakout Phase: New Partnerships, Zero Debt & $20 Million Growth Capital Position Company for 2026 Acceleration
- Finland's Gambling Reform Promises "Single-Click" Block for All Licensed Sites
- Private Keys Are a Single Point of Failure: Security Advisor Gideon Cohen Warns MPC Technology Is Now the Only Defense for Institutional Custody
The FDA approves these drugs only for children six and older, meaning young children are being prescribed potent stimulants "off-label" and without long-term safety research.
CCHR's Medicaid data collection three years later indicates the situation has not merely continued but likely worsened into a full-scale public-health failure demanding immediate federal intervention.
Jan Eastgate, president of CCHR International, says that these prescribing patterns reveal a federally funded "drug and polypharmacy pipeline"—one that urgently demands congressional and state oversight to protect children from what the watchdog calls "chemical assault and negligence disguised as care."
ADHD stimulant drugs carry a black box warning that they can cause addiction, even when taken exactly as prescribed.[2] A recent American Journal of Psychiatry study found that high doses of certain ADHD stimulants were associated with a more than five-fold increased risk of psychosis or mania.[3]
Danish physician and researcher Dr. Peter C. Gøtzsche warns that stimulants can also suppress normal childhood emotional and behavioral expression, causing apathy or indifference. In some studies, more than half of children developed depression or compulsive, and meaningless behaviors while taking them.[4]
Antidepressants also carry their own black box warning for suicidal thoughts and behavior in children and young adults.[5]
Antipsychotics are linked to metabolic damage, violent behavior, and neurological disorders.[6] One of their most severe effects is tardive dyskinesia (TD)—a disfiguring movement disorder caused by antipsychotics. Its symptoms resemble Parkinson's disease: involuntary movements of the lips, tongue, jaw, fingers, toes, or other body parts. TD can persist long after the drug is stopped—sometimes permanently. It is a reported risk in the pediatric population.[7]
Even worse, individuals developing TD are often prescribed more psychiatric drugs to counter the symptoms, exposing them to additional risks such as blurred vision, tremors, irregular heartbeat, drooling, restlessness, or akathisia—a well-documented driver of extreme agitation and suicidal or violent behavior.[8]
Eastgate says the expanding trend of drugging children with cocktails of psychotropics constitutes a national emergency: "This is a chemical assault on children, masking the real causes of their distress and too often worsening the very problems these drugs claim to treat. Federal and state intervention is urgently needed to abolish these negligent polypharmacy practices."
More on eTravel Wire
- Compliance Is the Ticket to Entry: Legal Advisor Gabriela Moraes Analyzes RWA Securitization Paths Under Brazil's New Legislation
- Coalition and CCHR Call on FDA to Review Electroshock Device and Consider a Ban
- Spark Announces 2025 Design Award Winners
- NEW Luxury Single-Family Homes Coming Soon to Manalapan - Pre-Qualify Today for Priority Appointments
- Dominic Pace Returns to the NCIS Franchise With Guest Role on NCIS: Origins
Clinical experts agree the system is out of control. Alexandra Perez, a clinical psychologist at Emory University School of Medicine, told The Wall Street Journal she has seen children as young as four years old who were already on multiple psychiatric drugs. Many of these children had histories of trauma or adversity that were mislabeled as ADHD and drugged instead of addressed through non-drug support.
A 2021 review in Frontiers in Psychiatry summarized more than 20 years of research documenting substantial growth in pediatric psychotropic polypharmacy. In the studies reviewed:
- Up to 300,000 U.S. youth were found to be receiving three or more psychiatric drug classes simultaneously in certain Medicaid datasets.
- In one large Medicaid study of individuals aged 2–24 treated for ADHD: use of two or more ADHD drugs rose from 16.8% to 20.5%; prescriptions for two or more additional psychotropic classes increased from 26.0% to 40.7%
- Another study reported that 73.1% of children aged 6–18 receiving ADHD drugs had psychotropic polypharmacy, versus 26.9% in younger (2–5) and older (19–24) groups.[9]
Four years after those findings, the Wall Street Journal shows the trend has only worsened, as confirmed also by CCHR's own Medicaid analysis. Between 2019 and 2022:
- Nearly 5,000 providers prescribed ADHD drugs to at least 100 children each
- On average, 25% of these children also received one or more additional psychiatric drugs
- By 2023, 39,000 children (23%) on ADHD drugs were taking two or more psychiatric drugs simultaneously, and more than 4,400 were on four separate drugs at once.
CCHR, founded 56 years ago by the Church of Scientology and professor of psychiatry Thomas Szasz, said the latest data reveal an entrenched national failure to protect children. "Pumping kids with ADHD stimulants—often amphetamines—combined with mind-altering antidepressants, antipsychotics, or sedative-hypnotics, is evidence of a mental health system that has normalized harm under the guise of treatment," Eastgate said. "This is not care—it is harm. The practice should be abolished."
Sources:
[1] Shalini Ramachandran, et al., "Millions of Kids Are on ADHD Pills. For Many, It's the Start of a Drug Cascade," Wall Street Journal, 20 Nov. 2025, www.wsj.com/health/wellness/kids-adhd-drugs-medication-06dfa0b7?st=oRRSe8&reflink=desktopwebshare_permalink
[2] www.cchrint.org/2023/05/16/fda-finally-adds-addiction-to-black-box-warning-on-adhd-drugs/; www.fda.gov/media/168066/download
[3] www.cchrint.org/2024/09/20/new-study-warns-of-high-dose-adhd-drugs-inducing-psychosis/; www.nbcnews.com/health/mental-health/high-doses-adhd-drugs-linked-greater-risk-psychosis-rcna170707
[4] Peter C. Gøtzsche, MD, "Critical Psychiatry Textbook, Chapter 9: ADHD (Part Two)," Mad In America, 14 Aug. 2023
[5] medshun.com/article/why-do-antipsychotics-cause-violence
[6] pmc.ncbi.nlm.nih.gov/articles/PMC3004713/; medshun.com/article/why-do-antipsychotics-cause-violence; psychiatryonline.org/doi/10.1176/appi.ps.201500272
[7] pubmed.ncbi.nlm.nih.gov/38862692/
[8] www.cchrint.org/2021/10/11/consumers-beware-of-antipsychotics-long-term-debilitating-effects/
[9] pmc.ncbi.nlm.nih.gov/articles/PMC8236612/
Source: Citizens Commission on Human Rights International
0 Comments
Latest on eTravel Wire
- From Cheer to Courtroom: The Hidden Legal Risks in Your Holiday Eggnog
- Controversial Vegan Turns Rapper Launches First Song, "Psychopathic Tendencies."
- Inside the Fight for Affordable Housing: Avery Headley Joins Terran Lamp for a Candid Bronx Leadership Conversation
- Canterbury Hotel Group Announces the Opening of the TownePlace Suites by Marriott Portland Airport
- Heritage at South Brunswick's Resort-Style Amenities for Any Age and Every Lifestyle
- Georgia's Lanier Islands Resort Pops the Cork on Two Wonderful Ways to Ring in the New Year
- T-TECH Partners with Japan USA Precision Tools for 2026 US Market Development of the New T-TECH 5-Axis QUICK MILL™
- Record Revenues, Debt-Free Momentum & Shareholder Dividend Ignite Investor Attention Ahead of 2026–2027 Growth Targets: IQSTEL (N A S D A Q: IQST)
- New YouTube Channel Pair Launches to Bring Entertainment Nostalgia Back to Life
- BRAG Hosts Holiday Benefit — Awards 10 Student Scholarships & Honors Timberland with the Corporate Impact Award
- FittingPros Launches Industry's First Data-Driven Golf Club Fitting Directory
- Take Control of Your Color Matching with Boston Industrial Solutions' Newly Expanded Natron® UVPX Series Ink Colors
- "Dr. Vincent Michael Malfitano Expands Monterey–Sicily Cultural Diplomacy With Major International Media Engagement"
- Kaufman Development Breaks Ground on Detroit Micro Data Center, Expanding Its National AI Platform
- Cummings Graduate Institute for Behavioral Health Studies Celebrates New DBH Graduates
- $80M+ Backlog as Florida Statewide Contract, Federal Wins, and Strategic Alliance Fuel Next Phase of AI-Driven Cybersecurity Growth: Cycurion $CYCU
- High-Conviction CNS Disruptor Aiming to Transform Suicidal Depression, Ketamine Therapeutics, and TMS - Reaching Millions by 2030
- Top10Christmas.co.uk Releases the UK Christmas Toy Trends 2025 Report
- Talagat Business Academy Announces Joint Certificate Program With The University of Chicago Booth School of Business
- LocaXion and Asseco CEIT Announce First-to-Market RTLS-Driven Digital Twin Platform for Healthcare, Manufacturing, and Logistics
